The FDA has granted priority review to a biologics license application for Pfizer’s respiratory syncytial virus vaccine candidate, RSVpreF, for adults aged ≥60 years.
RSV is back for the 2022-23 respiratory virus season and is unfamiliar to many. Click through this quick collection of myths already in circulation to prepare.
The FDA accepted the GSK BLA and granted priority review to what could be the first vaccine approved against RSV in adults aged ≥60 years, according to the company.
Topline phase 3 trial data showed 81.8% efficacy for the maternal vaccine against severe RSV-related illness in infants from birth through first 90 days of life.
The GSK RSV vaccine candidate has received favorable international regulatory attention which may be an auspicious sign for the US.
Your daily dose of clinical news you may have missed.
IDWeek 2022: New data show a greater than 60% reduction in acute exacerbations and need for antibiotics in patients with CS who used fluticasone propionate nasal spray.
The high-dose influenza vaccines provided greater relative vaccine effectiveness/efficacy vs standard dose in a cohort of more than 45 million.
CHEST. After a moderate COPD event, treatment with TT within 30 days significantly reduced risk for exacerbation over 12 months vs treatment after 30 days.